Breast Cancer Research and Treatment

, Volume 171, Issue 1, pp 75–84 | Cite as

Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)

  • Timothy J. Williamson
  • Susan M. Love
  • Jessica N. Clague DeHart
  • Alexandra Jorge-Miller
  • Leah Eshraghi
  • Heather Cooper Ortner
  • Annette L. StantonEmail author
Preclinical study



Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood—particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study’s aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors.


Participants (N = 515) with MBC were recruited from Dr. Susan Love Research Foundation’s Army of Women® and other advocacy organizations. Participants completed questionnaires of MBC-related collateral damage, depressive symptoms, anxiety, self-efficacy for managing oncologic treatments and physical symptoms, sleep, and physical activity.


Eight domains of MBC-related collateral damage, as well as MBC-related benefit finding, were reliably characterized. Concerns about mortality/uncertainty were most prominent. Participants also endorsed high levels of benefit finding. Participants younger than 50 years, with limited financial resources, or with children under 18 at home reported the most collateral damage. Collateral damage was associated significantly with compromised psychological health, lower illness management efficacy, and poorer health behaviors, beyond sociodemographic and medical characteristics.


Subgroups of MBC patients report long-term, life-altering consequences of MBC and its treatments, which relate to important health outcomes. Clinical implications and recommendations are discussed.


Metastatic breast cancer Quality of life Survivorship Supportive care Psycho-oncology Collateral damage 



We are grateful to the women and men who participated in this research. We are grateful to our advocate task force, including Cecilia Alvear (in memoriam), Dikla Benzeevi, Virginia Empey, Beth Fairchild, Michael Kovarik, Sheila McGlown, Carol Miele, RN, B.S., MPH, Lori Marx Rubiner (in memoriam), Sandra Spivey, Lynn Tramonte, Patricia Wu, Ed.D., and others, for their dedication to this research. This research was supported in part by a National Institute of Mental Health Predoctoral Fellowship (Williamson, MH 15750), the Breast Cancer Research Foundation (Stanton), Pfizer, Avon Breast Cancer Crusade, Celgene, Genentech, and Lilly Oncology.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This research complied with laws of the country in which it was performed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10549_2018_4823_MOESM1_ESM.docx (26 kb)
Supplementary material 1 (DOCX 26 KB)


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics (2018) CA Cancer J Clin 68(1):7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Reed E, Simmonds P, Haviland J, Corner J (2012) Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 43(4):747–758CrossRefPubMedGoogle Scholar
  5. 5.
    Slovacek L, Slovackova B, Slanska I, Petera J, Priester P (2010) Quality of life and depression among metastatic breast cancer patients. Med Oncol 27(3):958–959CrossRefPubMedGoogle Scholar
  6. 6.
    Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA (2004) Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat 87(1):45–57CrossRefPubMedGoogle Scholar
  7. 7.
    Lewis S, Willis K, Yee J, Kilbreath S (2016) Living well? Strategies used by women living with metastatic breast cancer. Qual Health Res 26(9):1167–1179CrossRefPubMedGoogle Scholar
  8. 8.
    Willis K, Lewis S, Ng F, Wilson L (2015) The experience of living with metastatic breast cancer-A review of the literature. Health Care Women Int 36(5):514–542CrossRefPubMedGoogle Scholar
  9. 9.
    Ewertz M, Jensen AB (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50(2):187–193CrossRefPubMedGoogle Scholar
  10. 10.
    Lash TL, Thwin SS, Yood MU, Geiger AM, Bosco J, Quinn VP et al (2014) Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer. Breast Cancer Res Treat 144(3):643–663CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Love SM, Bernstein L, Obidegwu O, Ottenbacher A, Eshraghi L, Clague J (2017) Collateral damage from metastatic breast cancer-preliminary results. Cancer Res. CrossRefGoogle Scholar
  12. 12.
    Eshraghi L, Ortner HC, DeHart JNC, Stanton A, Williamson T, Jorge A et al (2017) Metastatic breast cancer collateral damage (MBCCD) project: think tank of advocates and provider-survivors. J Clin Oncol 35(31_suppl):55CrossRefGoogle Scholar
  13. 13.
    Caplette-Gingras A, Savard J (2008) Depression in women with metastatic breast cancer: a review of the literature. Palliat Support Care 6(4):377–387CrossRefPubMedGoogle Scholar
  14. 14.
    Low CA, Stanton AL (2015) Activity disruption and depressive symptoms in women living with metastatic breast cancer. Heal Psychol 34(1):89–92CrossRefGoogle Scholar
  15. 15.
    Fulton CL (1997) The physical and psychological symptoms experienced by patients with metastatic breast cancer before death. Eur J Cancer Care 6(4):262–266CrossRefGoogle Scholar
  16. 16.
    Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A et al (2012) Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat 136(3):789–794CrossRefPubMedGoogle Scholar
  17. 17.
    Love AW, Grabsch B, Clarke DM, Bloch S, Kissane DW (2004) Screening for depression in women with metastatic breast cancer: a comparison of the Beck Depression Inventory short form and the Hospital Anxiety and Depression Scale. Aust N Z J Psychiatry 38(7):526–531CrossRefPubMedGoogle Scholar
  18. 18.
    Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP et al (2012) Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 12(2):119–126CrossRefPubMedGoogle Scholar
  19. 19.
    DiBonaventura MD, Copher R, Basurto E, Faria C, Lorenzo R (2014) Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Heal Drug Benefits 7(7):386–396Google Scholar
  20. 20.
    Hadji P, Ziller V, Kyvernitakis J, Schmidt N, Kostev K (2013) Persistence with bisphosphonates in patients with metastatic breast cancer: A retrospective database analysis. J Cancer Res Clin Oncol 139(7):1149–1155CrossRefPubMedGoogle Scholar
  21. 21.
    Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry K et al (2016) Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2− metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother 17(9):1189–1196CrossRefPubMedGoogle Scholar
  22. 22.
    Güth U, Huang DJ, Schötzau A, Schmid SM (2016) Use of palliative endocrine therapy in patients with hormone receptor-positive distant metastatic breast cancer: How often, how effective, how long? Oncology 90(1):1–9CrossRefPubMedGoogle Scholar
  23. 23.
    Koopman C, Nouriani B, Erickson V, Anupindi R, Butler LD, Bachmann MH et al (2002) Sleep disturbances in women with metastatic breast cancer. Breast J 8(6):362–370CrossRefPubMedGoogle Scholar
  24. 24.
    Mosher CE, DuHamel KN (2012) An examination of distress, sleep, and fatigue in metastatic breast cancer patients. Psychooncology 21(1):100–107CrossRefPubMedGoogle Scholar
  25. 25.
    Yee J, Davis GM, Beith JM, Wilcken N, Currow D, Emery J et al (2014) Physical activity and fitness in women with metastatic breast cancer. J Cancer Surviv 8(4):647–656CrossRefPubMedGoogle Scholar
  26. 26.
    Hublin C, Partinen M, Koskenvuo M, Kaprio J (2007) Sleep and mortality: A population-based 22-year follow-up study. Sleep 30(10):1245–1253CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Warburton DER, Nicol CW, Bredin SSD (2006) Health benefits of physical activity: the evidence. CMAJ 174(6):801–809CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rothrock NE, Kaiser KA, Cella D (2011) Developing a valid patient-reported outcome measure. Clin Pharmacol Ther 90(5):737–742CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Brod M, Tesler LE, Christensen TL (2009) Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res 18(9):1263–1278CrossRefPubMedGoogle Scholar
  30. 30.
    Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S et al (2010) The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 63(11):1179–1194CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gruber-Baldini AL, Velozo C, Romero S, Shulman LM (2017) Validation of the PROMIS® measures of self-efficacy for managing chronic conditions. Qual Life Res 26(7):1915–1924CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Jensen RE, King-Kallimanis BL, Sexton E, Reeve BB, Moinpour CM, Potosky AL et al (2016) Measurement properties of PROMIS sleep disturbance short forms in a large, ethnically diverse cancer cohort. Psychol Test Assess Model 58(2):353–370Google Scholar
  33. 33.
    Wagner LI, Schink J, Bass M, Patel S, Diaz MV, Rothrock N et al (2015) Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer 121(6):927–934CrossRefPubMedGoogle Scholar
  34. 34.
    Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D et al (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 13(7):625–635CrossRefPubMedGoogle Scholar
  35. 35.
    Child D (1990) The essentials of factor analysis. Cassell Educational, LondonGoogle Scholar
  36. 36.
    Hu LT, Bentler PM (1995) Evaluating model fit. In: Hoyle RH (ed) Structural equation modeling: concepts, issues, and applications. Sage Publications, Thousand Oaks, pp 76–99Google Scholar
  37. 37.
    Wiley JF, Gruenewald TL, Karlamangla AS, Seeman TE (2016) Modeling multisystem physiological dysregulation. Psychosom Med 78(3):290–301CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Peppercorn JM, Smith TJ, Helft PR, DeBono DJ, Berry SR, Wollins DS et al (2011) American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 29:755–760CrossRefPubMedGoogle Scholar
  39. 39.
    Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith M, Lou SJ et al (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30(34):4249–4255CrossRefPubMedGoogle Scholar
  40. 40.
    Cella DF, Tulsky DS, Gray G (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579CrossRefPubMedGoogle Scholar
  41. 41.
    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405CrossRefPubMedGoogle Scholar
  42. 42.
    Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11(2):96–110CrossRefPubMedGoogle Scholar
  43. 43.
    Ashing-Giwa KT, Lim JW (2009) Examining the impact of socioeconomic status and socioecologic stress on physical and mental health quality of life among breast cancer survivors. Oncol Nurs Forum 36(1):79–88CrossRefPubMedGoogle Scholar
  44. 44.
    Chino F, Peppercorn J, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP et al (2014) Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 19(4):414–420CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Schlegel RJ, Manning MA, Molix LA, Talley AE, Bettencourt BA (2012) Predictors of depressive symptoms among breast cancer patients during the first year post diagnosis. Psychol Health 27(3):277–293CrossRefPubMedGoogle Scholar
  46. 46.
    Bloom JR, Stewart SL, Chang S, Banks PJ (2004) Then and now: quality of life of young breast cancer survivors. Psychooncology 13(3):147–160CrossRefPubMedGoogle Scholar
  47. 47.
    DeShields T, Tibbs T, Fan MY, Taylor M (2006) Differences in patterns of depression after treatment for breast cancer. Psychooncology 15(5):398–406CrossRefPubMedGoogle Scholar
  48. 48.
    Bright EE, Stanton AL (2018) Prospective investigation of social support, coping, and depressive symptoms: a model of adherence to endocrine therapy among women with breast cancer. J Consult Clin Psychol 86(3):242–253CrossRefPubMedGoogle Scholar
  49. 49.
    Thornton LM, Andersen BL, Carson WE (2008) Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol Immunother 57(10):1471–1481CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Harvey AG (2002) Trouble in bed: the role of pre-sleep maintenance of insomnia. J Cogn Psychother 16(2):161–177CrossRefGoogle Scholar
  51. 51.
    Harvey AG (2000) Pre-sleep cognitive activity: a comparison of sleep-onset insomniacs and good sleepers. Br J Clin Psychol 39(3):275–286CrossRefPubMedGoogle Scholar
  52. 52.
    Yancey AK, Ortega AN, Kumanyika SK (2006) Effective recruitment and retention of minority research participants. Annu Rev Public Health 27(1):1–28CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychologyUniversity of CaliforniaLos AngelesUSA
  2. 2.Dr. Susan Love Research FoundationEncinoUSA
  3. 3.Department of Population SciencesBeckman Research Institute of City of HopeDuarteUSA
  4. 4.Department of Psychiatry and Biobehavioral SciencesUniversity of CaliforniaLos AngelesUSA
  5. 5.Jonsson Comprehensive Cancer CenterUniversity of CaliforniaLos AngelesUSA
  6. 6.Cousins Center for PsychoneuroimmunologyUniversity of CaliforniaLos AngelesUSA

Personalised recommendations